Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Operating Leases (2019 - 2025)

Outlook Therapeutics (OTLK) has disclosed Operating Leases for 4 consecutive years, with $171988.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 26.22% to $171988.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $171988.0 through Dec 2025, down 26.22% year-over-year, with the annual reading at $188801.0 for FY2025, N/A changed from the prior year.
  • Operating Leases for Q4 2025 was $171988.0 at Outlook Therapeutics, down from $188801.0 in the prior quarter.
  • The five-year high for Operating Leases was $233113.0 in Q4 2024, with the low at $171988.0 in Q4 2025.